VERTEX PHARMACEUTICALS INC / MA (VRTX) has a notice of proposed sale filed for shares of its common stock under Rule 144. Director Bruce I. Sachs plans to sell 1,210 shares of Vertex common stock through Goldman Sachs & Co. LLC, with an indicated aggregate market value of $662,535.50. The shares were acquired as a gift and are held jointly with Kimberlie T. Sachs as JTWROS. As of this notice, 253,460,924 shares of Vertex common stock were outstanding, and the shares are listed on NASDAQ. The remark states that shares are sold through the Watercove Charitable Foundation, where Bruce I. Sachs serves as trustee.
Vertex Pharmaceuticals reported strong Q2 2026 results, with total revenues of $3.33 billion versus $2.96 billion a year earlier and first‑half revenues of $6.32 billion versus $5.73 billion. Net income was $1.10 billion for the quarter and $2.13 billion year‑to‑date, with diluted EPS of $4.31 and $8.33, respectively. Growth was driven by cystic fibrosis therapies overall, particularly ALYFTREK, and expanding contributions from CASGEVY and JOURNAVX, while TRIKAFTA/KAFTRIO revenue declined modestly.
Income from operations reached $1.25 billion in Q2. Cost of sales rose to 14.7% of net product revenue, reflecting product mix. R&D spending was stable at $1.96 billion for the first half, while SG&A increased to $582.2 million in Q2 and $1.08 billion year‑to‑date as the company invested in new product launches. Operating cash flow strengthened to $2.55 billion in the first half.
Liquidity remains significant, with $13.64 billion in cash, cash equivalents and marketable securities and working capital of $8.61 billion as of June 30, 2026. Vertex repurchased 1.8 million shares for $799.5 million in the first half and has $2.6 billion remaining under its 2025 repurchase program. Strategically, it agreed to acquire Crinetics Pharmaceuticals for approximately $10.0 billion, backed by a new $4.5 billion term loan facility and a $500 million revolving credit facility, both currently undrawn, while also addressing an arbitration over ALYFTREK royalty rates.
Vertex Pharmaceuticals reported Q2 2026 revenue of $3.33 billion, up 12% year over year, driven by cystic fibrosis products and growing contributions from CASGEVY and JOURNAVX. GAAP net income was $1.10 billion (diluted EPS $4.31); non-GAAP net income was $1.21 billion (EPS $4.73).
Cash, cash equivalents and marketable securities totaled $13.6 billion as of June 30, 2026, reflecting strong operating cash flow partially offset by share repurchases. The company raised full-year 2026 revenue guidance to $13.1–$13.2 billion, embedding expectations for $0.5 billion or more of non-CF product revenue.
Vertex highlighted rapid uptake of CASGEVY and JOURNAVX, an FDA PDUFA date of November 30, 2026 for IgAN drug povetacicept, and an agreement to acquire Crinetics Pharmaceuticals for about $10.0 billion, adding a rare endocrine disease portfolio.
Vertex Pharmaceuticals reported a compensation-related equity grant to EVP and Chief Regulatory & Quality Officer Ourania Tatsis. She acquired 8,251 shares of common stock in the form of a restricted stock unit award on 07/21/2026, vesting on 03/31/2030, bringing her direct holdings to 53,572 shares.
Vertex Pharmaceuticals executive Amit Sachdev reported an acquisition of 8,251 shares of common stock on 2026-07-21 through a restricted stock unit award that vests on 03/31/2030. Following this award, he holds 66,512 shares directly, plus 882 shares indirectly via a 401(k) and 6,637 shares held in trust.
SACHS BRUCE I reported acquisition or exercise transactions in this Form 4 filing.
Vertex Pharmaceuticals director Bruce I. Sachs received a grant of 99.941 deferred stock units on July 15, 2026 at $475.28 per unit. Each unit represents one share of common stock, payable upon his board service ending, a change of control, disability, or death, bringing his directly held deferred stock units to 15,771.807.
Garber Alan M reported acquisition or exercise transactions in this Form 4 filing.
Vertex Pharmaceuticals director Alan M. Garber received a grant of 31.56 deferred stock units on July 15, 2026. Each unit represents one share of common stock and will be paid in shares upon the earliest of his board service termination, a change of control, or his disability or death. Following this award, he directly holds 65.458 deferred stock units tied to Vertex common stock.
Vertex Pharmaceuticals executive Ourania Tatsis reported an open-market sale of 1,500 shares of Common Stock. The transaction took place on July 2, 2026 at a price of $524.99 per share. The filing states that the sale was made pursuant to a company-approved Rule 10b5-1 trading plan entered into on August 21, 2025, indicating it was pre-scheduled. After this transaction, Dr. Tatsis directly holds 45,321 shares of Vertex Pharmaceuticals common stock.
Vertex Pharmaceuticals executive Duncan McKechnie, EVP and Chief Commercial Officer, sold 1,541 shares of Common Stock in an open-market transaction at $519.00 per share on July 2, 2026. Following this sale, he directly holds 11,001 shares. The transaction was made under a company-approved trading plan pursuant to Rule 10b5-1 entered into on November 25, 2025, indicating it was pre-scheduled rather than discretionary.
Vertex Pharmaceuticals plans to acquire Crinetics Pharmaceuticals in an all-cash deal at $85.00 per share, implying a $10.0 billion equity value, or $8.8 billion net of cash. Crinetics will become a wholly owned subsidiary following the merger, which is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals.
Vertex expects to finance the transaction with cash on hand and a $4.5 billion unsecured 364‑day bridge loan facility. Management highlights the commercialized acromegaly drug PALSONIFY and late‑stage atumelnant for congenital adrenal hyperplasia as key strategic assets, targeting more than $5 billion in potential annual revenue and accretion to non‑GAAP operating income in 2029.